N02.2: Hematuria Rekuren dan Persisten dengan Glomerulonefritis Membranosa Difus

KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney International Supplements. 2021;11(1):1-274.

Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21.

Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566-574.

Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013;9(8):443-458.

Ponticelli C, Glassock RJ. Glomerular diseases: membranous nephropathy - the most common cause of nephrotic syndrome in adults. Preface. Adv Chronic Kidney Dis. 2021;28(4):263-264.

Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):319-330.

Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol. 2008;3(3):905-919.

Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348-358.

World Health Organization. ICD-10 Classification of Diseases and Related Health Problems. 10th Revision. Geneva: WHO; 2019.

Indonesian Nephrology Association. Panduan Praktik Klinis Penyakit Ginjal. Jakarta: PB PPNI; 2020.